Abstract:Objective: This study aimed to evaluate the effectiveness and safety of Allisartan Isoproxil in the management of hypertension. Methods: A comprehensive search was conducted across both English and Chinese databases, including the Cochrane Library, Embase, PubMed, Web of Science, Chinese Journal Full Text Database (CNKI), Wanfang Digital Periodical Full Text Database, and VIP Chinese Periodical Database (VIP), up to March 24, 2024. Randomized controlled trials (RCTs) investigating alisartan axetil for hypertension management were selected. Literature quality was assessed, and data were extracted for meta-analysis using Stata 15.1 software. The quality of evidence for outcome indicators was evaluated using the GRADE system level. Results: Six RCTs involving 767 participants were included. Meta-analysis revealed that, compared to placebo, the Allisartan Isoproxil group exhibited a significant reduction in systolic blood pressure (SBP) [WMD = −8.08, 95% CI (−11.81, 4.10), p = 0.000] and brachial-ankle pulse wave velocity (baPWV) [SMD = −0.69, 95% CI (−1.17, 0.20), p = 0.006]. However, the reduction in diastolic blood pressure (DBP) was not statistically significant [WMD = −5.48, 95% CI (−11.07, 0.10), p = 0.054]. Additionally, compared to calcium channel blockers (CCB) and angiotensin II receptor blockers (ARB), Allisartan Isoproxil did not significantly affect SBP [WMD = 0.20, 95% CI (−3.71, 4.10), p = 0.921] or DBP [WMD = 0.16, 95% CI (−2.11, 2.43), p = 0.891]. Allisartan Isoproxil demonstrated superior effects in increasing nitric oxide (NO) levels and decreasing endothelin (ET) levels compared to control groups [WMD = 9.56, 95% CI (6.42, 12.71), p = 0.000], [WMD = −7.42, 95% CI (−11.13, −3.71), p = 0.000], and showed a higher effective control rate of blood pressure [RR = 1.26, 95% CI (1.13, 1.41), p = 0.000]. Subgroup analysis did not reveal significant differences. Regarding safety, there were no statistically significant differences in adverse events between the Allisartan Isoproxil group and the control groups [RR = 0.99, 95% CI (0.74, 1.32), p = 0.928], and no fatal adverse events were reported. Conclusion: Allisartan Isoproxil is effective in reducing SBP and baPWV, increasing NO, decreasing ET, and achieving a higher control rate of blood pressure in patients with essential hypertension. These benefits are achieved with minimal adverse reactions. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023467869, identifier PROSPERO CRD42023467869.

Meta-analysis of losartan and captopril in treatment of essential hypertension:comparing the efficacy and adverse re-actions

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Efficacy Comparison Between 5 Mg Perindopril Arginine Salt and 4 Mg Perindopril Tert-Butylamine Salt for Patients with Mild to Moderate Essential Hypertension

The effect of captopril on endothelin of cardiovascular tissues in spontaneously hypertensive rats

Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension

Efficacy of Losartan versus Enalapril in Treatment of Mild and Moderate Hypertension

A Comparison of Initial Treatment with Losartan/hctz Versus Losartan Monotherapy in Chinese Patients with Mild to Moderate Essential Hypertension.

Effect Different Medicine on Serum Uric Acid in Patients with Hypertension

Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis

A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

A Multi-Center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Chinese Patients with Symptomatic Heart Failure Intolerant of Angiotensin Converting Enzyme Inhibitor Treatment.

PS 17-77 A RANDOMIZED, DOUBLE-BLIND AND DOUBLE-DUMMY, MULTIPLE-DOSE, POSITIVE AND PARALLEL COMPARATIVE, MULTICENTER CLINICAL TRIAL OF ALLISARTAN EVALUATE EFFICACY AND SAFETY IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION

Protective Effect of Levamlodipine on Renal Function in Patients with Essential Hypertension: A Meta-analysis

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

Meta-analysis of Effectiveness and Safety of Levoamlodipine and Amlodipine for Essential Hypertension

Comparative Effectiveness of Traditional Chinese Medicine vs. Losartan on Blood Pressure: Real-World Insights from RCT-Eligible Populations

Effect on Blood Pressure Control of Switching from Valsartan Monotherapy to Losartan/hydrochlorothiazide in Asian Patients with Hypertension: Results of a Multicentre Open-Label Trial

Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis

The Antihypertensive Efficacy and Safety of Benazepril in Chinese Population: a Meta-Analysis of Randomized Controlled Trials

Effects of traditional Chinese patent medicine on essential hypertension: a systematic review